Clinical Trial Information Request for Protocol 19-743 Title A phase 2 study of MRD adapted therapy with venetoclax-obinutuzumab in patients with relapsed or refractory CLL, with addition of acalabrutinib in patients with persistent MRD PI Site Directions: Type your name, contact email and phone number (optional) into the boxes below then click Save to Submit your request for information about this study. Name Email Phone